Price
$5.43
Decreased by -6.86%
Dollar Volume (20D)
7.58 M
ADR%
8.16
Earnings Report Date (estimate)
May 13, 24
Shares Float
80.69 M
Shares Outstanding
112.78 M
Shares Short
10.48 M
Market Cap.
657.54 M
Beta
2.37
Price / Earnings
N/A
20D Range
4.39 6.72
50D Range
3.81 6.72
200D Range
1.11 6.72
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
May 13, 24 0
Increased by +100%
-0.17
Increased by +100%
Mar 21, 24 -0.25
Decreased by -19.05%
-0.25
Nov 14, 23 -0.24
Increased by +20%
-0.23
Decreased by -4.35%
Aug 14, 23 -0.45
Decreased by -40.63%
-0.24
Decreased by -87.5%
May 15, 23 -0.26
Increased by +21.21%
-0.24
Decreased by -8.33%
Mar 30, 23 -0.21
Increased by +25%
-0.25
Increased by +16%
Nov 9, 22 -0.3
Increased by +9.09%
-0.28
Decreased by -7.14%
Aug 11, 22 -0.32
Increased by +86.61%
-0.3
Decreased by -6.67%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 744 K
Decreased by -68.59%
-21.99 M
Increased by +19.31%
Decreased by -2.96 K%
Decreased by -156.91%
Jun 30, 23 3.37 M
Increased by +236.03%
-41.67 M
Decreased by -45.3%
Decreased by -1.24 K%
Increased by +56.76%
Mar 31, 23 1.27 M
Increased by +54.95%
-23.36 M
Increased by +20.81%
Decreased by -1.84 K%
Increased by +48.89%
Dec 31, 22 1.56 M
Increased by +7.23%
-19.47 M
Increased by +22.63%
Decreased by -1.25 K%
Increased by +27.85%
Sep 30, 22 2.37 M
Increased by +53.93%
-27.26 M
Decreased by -15.34%
Decreased by -1.15 K%
Increased by +25.07%
Jun 30, 22 1 M
Increased by +37.64%
-28.68 M
Increased by +30.38%
Decreased by -2.86 K%
Increased by +49.42%
Mar 31, 22 819 K
Decreased by -22.95%
-29.49 M
Decreased by -169.06%
Decreased by -3.6 K%
Decreased by -249.22%
Dec 31, 21 1.45 M
Decreased by -46.77%
-25.17 M
Decreased by -409.54%
Decreased by -1.73 K%
Decreased by -857.31%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.